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Abstract: Constrained peptidomimetic scaffolds are of con-
siderable interest for the design of therapeutically useful an-
alogues of bioactive peptides. We present the single-step
cyclization of (S)- or (R)-a-hydroxy-b2- or a-substituted-a-hy-
droxy-b2, 2-amino acids already incorporated within oligopep-
tides to 5-aminomethyl-oxazolidine-2,4-dione (Amo) rings.
These scaffolds can be regarded as unprecedented b2- or
b2, 2-homo-Freidinger lactam analogues, and can be
equipped with a proteinogenic side chain at each residue. In
a biomimetic environment, Amo rings act as inducers of ex-
tended, semi-bent or folded geometries, depending on the
relative stereochemistry and the presence of a-substituents.
Introduction
Although native biologically active peptides have great poten-
tial for medical and biotechnological applications,[1] their utility
is reduced by severe inherent limitations, in particular poor sta-
bility against proteolytic breakdown and restricted biodistribu-
tion and bioavailability.[2] Peptides also tend to be quite flexi-
ble, and conformations are highly dependent on the environ-
ment, leading to modest receptor selectivity. These issues have
been addressed by the design of highly stable and conforma-
tionally constrained peptidomimetics ;[1, 2] that is, compounds
with pharmacophoric and stereostructural elements that mimic
the bioactive structure of the parent peptides.[3]
One approach to obtaining more rigid peptidomimetics[1–3]
is to incorporate local constraints using conformationally re-
stricted amino acid units or modified peptide backbones.
Global constraints are introduced for instance through cycliza-
tion or by replacing portions of the peptides with nonpeptide
structures. In this context, significant effort has been dedicated
to the design of scaffolds that mimic turn structures. b-Turns
are common motifs in peptide structures (Figure 1), and they
are very often critical to peptide conformational stability, with
many interactions correlated to a variety of biological process-
es.[3, 4] Native b-turns involve four residues with Ca(i) to Ca(i+3)
distances of less than 7.0 , and form a hydrogen-bond C=
O(i)···HN(i+4) (1 7!4-type).[5] As a consequence, small scaffolds
that reproduce these features have been extensively investi-
gated to discover compounds that can mimic or disrupt turn-
mediated recognition events.[6] For instance, the prototypic
Freidinger lactam dipeptides[2, 4, 7] have been widely used to
constrain peptide conformations, stabilizing turn structures
and acting as strand inducers (Figure 1).[8]
However, the scaffold strategy has so far resulted in limited
success with bioactive peptide ligands for which the nonpep-
tide or pseudopeptide scaffold itself contains most of the phar-
macophore elements.[3, 6] Frequently, the side chains at some
fundamental positions are not maintained, or one of the
amino acids is omitted on the basis of the hypothesis that
some residues play a structural rather than a recognition role;
for example, Pro or Gly at position i + 1 of a b-turn.[6, 9] There-
fore, the structures of the turn mimetics may lack some rele-
vant pharmacophores for specific targets. An example is repre-
sented by the early Freidinger lactams (Figure 1) obtained by
sacrificing the i + 1 side chain with the formation of five- to
eight-membered rings. To overcome this limit, much effort has
been dedicated to the preparation of a-substituted lactams;[10]
for instance, Palomo et al. proposed the separation of con-
straint and recognition elements, and introduced a-alkyl-a-
amino-b-lactam rings placed at the position i + 1 residue as
potent nucleators of b-turns (Figure 1).[11]
Furthermore, the preparation of constrained mimetics may
require multistep procedures, resulting in low overall yields,
and many synthetic methods lack flexibility and are therefore
not suited to the introduction of diversity.[6] As a consequence,
the development of an expedient procedure with which to
Figure 1. Sketch of a b-turn, a classic Freidinger lactam, and the a-amino-b-
lactam approach.
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constrain a peptide while maintaining all of the pharmaco-
phores is of considerable interest.
In the last few years, we have been interested in the rapid
and simple ring closure of b-hydroxy-a-amino acids into turn-
inducer scaffolds. Very recently, we observed that the reaction
of N-arylsulfonyl-peptides containing l- or d-configured Ser
and/or other b-hydroxy-a-amino acids (Thr, PhSer), with N,N’-
disuccinimidyl carbonate (DSC) and a catalytic amount of diiso-
propylethylamine (DIPEA), gave rise in a single step to the for-
mation of oxazolidinone (Oxd) ring(s) (Scheme 1).[12] Under the
same conditions, the corresponding Fmoc- or Boc-peptides
gave elimination to dehydroalanine, in agreement with previ-
ous reports,[13] suggesting that the N-sulfonyl group effectively
promoted the cyclization.
In this paper we describe a single-step procedure to lock
the geometry of a oligopeptide by cyclization of a-hydroxy-b2-
amino acids or a-substituted-a-hydroxy-b2, 2-amino acids, al-
ready present in the sequence, to 5-aminomethyloxazolidine-
2,4-dione rings (Amo). These unusual heterocyclic scaffolds
(Scheme 1 and Figure 2) can be regarded as b2- or b2, 2-homo
variants of a classic Freidinger lactam and can be equipped
with a side chain at each a-position.
Results and Discussion
Synthesis
On repeating the same protocol depicted in Scheme 1 with
a peptide containing the a-hydroxy-b2-amino acid isoserine
(isoSer) , we observed, as could have been expected, a different
outcome: the reaction led exclusively to cyclization to give 5-
aminomethyloxazolidine-2,4-dione (Amo) comprising isoSer
and the following amino acid (Scheme 1). To our knowledge,
this peptide represents the first example of a conformationally
constrained peptide containing an oxazolidine-2,4-dione scaf-
fold; in general, this heterocycle has been described and uti-
lized very few times in organic or medicinal chemistry.[14]
From a structural point of view, Amo can be regarded as
a novel constrained b2-amino acid. Among the b-amino acids,
the b2-amino acids are less synthetically feasible with respect
to their b3-counterparts (Figure 2).[15] Moreover, the cyclic struc-
ture of Amo, achieved through acylation of the backbone ni-
trogen atom, embraces two consecutive amino acids, therefore
introducing a global constraint of C(i)N(i+1) type[3a] in the se-
quence. This kind of short-range cyclization[16] can significantly
reduce the conformational space accessible to the peptide
segment in which they are incorporated. In this context, the
Amo ring can be regarded as a novel b2-homo analogue of
a Freidinger lactam (Figure 2).[17] Structures combining the con-
formational properties of the Freidinger lactams with the sta-
bility of the b-amino acids have been the subject of much in-
terest by Gmeiner and co-workers and by some other
groups;[18] however, in all cases the reported structures were
b3-homo variants of Freidinger lactams (Figure 2).
Finally, the Amo-Phe sequence of Scheme 1 might also rep-
resent a constrained dipeptide unit composed of b2 and a resi-
dues, which is of potential interest for the design of a/b-
hybrid foldamers[19] showing unprecedented secondary struc-
tures (see also the Conformational Analysis Section). Indeed,
unexpected conformational effects have often been observed
when b2-amino acids were present in the backbone instead of
the more common b3 residues.[15a]
This potential interest prompted us to exploit the cyclization
to prepare oligopeptide sequences containing the unusual
scaffold under different reaction conditions. Accordingly, we
prepared a mini-library of di-, tri- or tetrapeptides containing
(S)- or (R)-configured isoSer, equipped with different groups at
the N-terminus, and amide or ester at the C-terminus
(Scheme 2), and we reacted these peptides with different car-
bonates or dicarbonates, either in solution (Scheme 3, Table 1)
or in the solid phase (Scheme 4, Table 1).The dipeptide Boc-
Scheme 1. Reaction of peptides containing Ser (top) or isoSer (bottom) with
DSC.
Figure 2. Structures of b2-, b2, 2-, and b3-amino acids (top), and comparison of
a classic Freidinger lactam composed of all a-amino acids (middle), with the
b2- and b2, 2-homo Amo variants, and with a Gmeiner’s b3-homo lactams[18]
(bottom).
Scheme 2. Synthesis of isoSer-containing peptides 1 and 2.
Chem. Eur. J. 2014, 20, 13390 – 13404 www.chemeurj.org  2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim13391
Full Paper
isoSer-PheNH2 (1 a) was prepared in solution by coupling Boc-
isoSerOH and H-PheNH2 under MW irradiation,
[20] using HBTU/
1-hydroxybenzotriazole (HOBt)/DIPEA as activating agents
(Scheme 2, Step i). Boc-isoSerOH[21] was prepared according to
a published procedure. The isoSer building block was incorpo-
rated without protection of the OH function. Under these reac-
tion conditions,[12] the acylation of the OH-function and thus
the formation of a depsipeptide side product was not ob-
served, as confirmed by 1H NMR and RP-HPLC MS analyses of
the crude reaction mixture. After purification by flash chroma-
tography over silica gel, 1 a was utilized for the following cycli-
zation step (Scheme 3, Table 1).
By using the same protocol, Boc-isoSerOH and (R)-H-PheNH2
gave 1 b, whereas (R)-Boc-isoSerOH[21] and H-PheNH2 gave 1 c.
The tripeptides 1 d and 1 e were prepared from Boc-isoSerOH
and H-Phe-ValOMe (1 d), or (R)-Boc-isoSerOH and H-Phe-
ValOMe (1 e). The crude compounds 1 b–e were analyzed by
RP-HPLC MS and utilized as intermediates for the preparation
of longer sequences without further purification. The dipeptide
H-Phe-ValOMe was prepared, in turn, from Boc-Phe-ValOMe,[22]
by treatment with 25 % trifluoroacetic acid (TFA) in dichlorome-
thane (CH2Cl2). The same conditions were utilized for Boc de-
protection of the di- or tripeptides 1 a–e (Scheme 2).
The peptide-TFA salts from 1 a–e were subjected to coupling
with Tosyl (Ts)-AlaOH under the conditions described above, to
give the corresponding tri- or tetrapeptides 2 a–e (Scheme 2).
Ts-AlaOH was prepared as described in a published proce-
dure.[23] Finally, tetrapeptide 2 d was obtained from 1 d and
Boc-AlaOH. The tri- or tetrapeptides 2 a–f were isolated by
flash chromatography over silica gel, and their structures were
assigned by 1H NMR and HPLC-MS analyses.
The reaction of Ts-tripeptides 2 a and 2 b, containing (S)- or
(R)-isoSer, and of the diastereoisomeric 2 c, with DSC and
DIPEA for 1 h in CH2Cl2/N,N-dimethylformamide (DMF) gave
the corresponding Amo-peptides 3 a–c with excellent yields
(Scheme 3, Table 1, entries 1–3). Other carbonates or dicarbon-
ates gave inferior results [Table 1, entry 4 (triphosgene 55 %),
entry 5 (Boc2O traces), entry 6 (CDI 70 %)]. Good yields were
obtained with DSC for the synthesis of tetrapeptides 3 d–f
having Val methyl ester at the C-terminus (entries 7–9), and for
the minimalist dipeptide Boc-Amo-PheNH2 3 g (entry 10).
Different protecting groups at the N-terminus such as Boc
(entries 9 and 10) and Ac (entry 11), gave results that were very
similar to those obtained with Ts protection. Clearly, for the
comparatively simple cleavage, carbamate protecting groups
represent the most obvious choice.[24] Nevertheless, several
methods have been published for the mild cleavage of arylsul-
fonyl groups.[24, 25] Recently, we successfully removed the Ts
group from peptides containing the Oxd ring with iodotrime-
thylsilane,[12, 26] whereas treatment with SmI2–pyrrolidine–
water[27] was less efficient.
The Ac-peptide 2 h was prepared as a mixture of diastereo-
isomers from racemic isoSer (not protected at the OH function)
by solid-phase synthesis (Scheme 4). N-Fmoc-protected amino
acids were coupled on a standard Wang resin with HBTU/
HOBt/DIPEA under MW irradiation (45 8C).[12] Fmoc deprotec-
tion was performed with 20 % piperidine in DMF under MW ir-
radiation. The resulting resin-bound peptide Ac-Ala-(S/R)-
isoSer-Phe-Wang was then utilized for the following cyclization
Scheme 3. Regioselective cyclization of isoSer-containing peptides 1 a and 2
to Amo-peptides 3.
Table 1. Cyclization of peptides 1 a and 2 containing isoSer to Amo-pep-
tides 3.
Entry 1/2 R isoSer Phe R’ Carbonate 3 Yield [%][a]
1 2 a Ts-Ala S S NH2 DSC a 93
2 2 b Ts-Ala R S NH2 DSC b 90
3 2 c Ts-Ala S R NH2 DSC c 93
4 2 a Ts-Ala S S NH2 triphosgene a 55
5 2 a Ts-Ala S S NH2 Boc2O a trace
6 2 a Ts-Ala S S NH2 CDI a 70
7 2 d Ts-Ala S S ValOMe DSC d 90
8 2 e Ts-Ala R S ValOMe DSC e 93
9 2 f Boc-Ala S S ValOMe DSC f 91
10 1 a Boc S S NH2 DSC g 91
11 2 h[b] Ac-Ala S/R S Phe-Wang DSC h[c] 80[d]
[a] After isolation by semipreparative RP-HPLC, see General Methods.
[b] Ac-isoSer-Phe-Wang resin. [c] Ac-Amo-PheOH. [d] Calculated after
cleavage from the Wang resin, based on an average resin loading of
0.6 mmol g1.
Scheme 4. Solid-phase synthesis of Ac-tripeptides 3 h.
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prior to cleavage by treatment with a moderate excess of DSC
(3 equiv) and DIPEA (1 equiv) in 4:1 CH2Cl2/DMF for 2 h. Cleav-
age from resin was performed with TFA in CH2Cl2 in the pres-
ence of scavengers.
Analysis of the crude reaction mixture by RP-HPLC and ESI-
MS revealed the presence of the two diastereomeric Amo-pep-
tide acids Ac-Ala-(S/R)-Amo-PheOH (3 h) in 1:1 ratio, which
were recovered in very satisfactory yield (80 %, based on an
average resin loading of 0.6 mmol g1) after semipreparative
RP-HPLC (General Methods).
In all cases, epimerization during the cyclization of 2 a–h
was excluded on the basis of the NMR and HPLC analyses, in-
cluding HPLC analysis on a chiral stationary phase (see General
Methods).
The structure of the ring-closing products 3 was readily de-
termined by 1H NMR and gCOSY analyses. The disappearance
of the PheNH resonance in the 1H NMR spectrum, a significant
downfield shift of PheHa, and the loss of the PheHa-PheNH
coupling constant, established the acylation of the adjacent
Phe nitrogen. In contrast, the proton pattern of the isoSer resi-
due was maintained (apart from the OH group), and the reso-
nances of the Ala residue were practically unaffected.
In principle, the cyclization of the isoSer residue with DSC
could also give rise to the formation of an oxazolidin-2-one
(Oxd) ring (Scheme 3, Path b); this was obtained as the only
product in peptides containing Ser (Scheme 1) or other b-hy-
droxy-a-amino acids. The concomitant formation of traces of
oxazolidinones by alternative cyclization was excluded on the
basis of the HPLC, MS, and 1H NMR analyses of the crude reac-
tion mixtures. Apparently, all reactions of 2 a–h proceeded
with complete regioselectivity, giving the Amo ring exclusively.
This observation prompted us to verify whether the ring clo-
sure to Oxd occurred when the former was prevented by
choosing sarcosine (Sar, N-methylglycine), as the C-terminal
amino acid. Consequently, we synthesized the tripeptide Ts-
Ala-isoSer-SarNH2 (2 i), and attempted the cyclization reaction
under the same conditions as before (Scheme 5). In effect,
after 1 h, cyclization to the corresponding peptide Ts-Ala-Oxd-
SarNH2 (4) was observed, albeit in low yield (25 %) compared
with that obtained with the Amo-peptides 3, the rest being
the intermediate isoSer-O-carbonate. The yield was improved
to 55 % by using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU;
1 equiv) instead of catalytic DIPEA, an excess of DSC (3 equiv),
higher temperatures (40 8C), and prolonged reaction times
(6 h). Apparently, the cyclization to Amo 3 seems to be favored
over the alternative cyclization to Oxd 4.
Presumably, cyclization to Amo proceeds through the five-
membered anionic intermediate with endocyclic C=O
(Scheme 3, Path a, and the Supporting Information). The loss
of 2,5-dioxopyrrolidin-1-olate leaving group, rapidly protonated
by DIPEAH+ , leads to Amo-peptide 3 and DIPEA (which can be
utilized in a catalytic amount). A detailed study of the reaction
mechanism is beyond the scope of this work. Preliminary com-
putations (see the Supporting Information) suggested that the
intermediate with endocyclic C=O is significantly more stable
than the alternative intermediate with exocyclic C=O
(Scheme 3, Path b), precursor of the Oxd.
The Amo ring proved to be remarkably stable when dis-
solved in common organic solvents and in water. On the other
hand, it has been reported that the carbamate increased the
reactivity of the inner peptide bond towards reduction by
NaBH4.
[14] Accordingly, 3 b was regioselectively reduced at the
4-position of the five-membered ring in very satisfactory yield,
giving exclusively 4-hydroxy-5-aminomethyl oxazolidin-2-one 5
in trans relative stereochemistry (Scheme 6).
The trans-relationships between the two substituents was
substantiated by the very small J(H4,H5) coupling constant in
the 1H NMR spectrum. 4,5-Disubstituted trans-oxazolidin-2-
ones are characterized by coupling constants that are much
lower than those of the cis-stereoisomers[28] (equilibrium be-
tween anomers was not observed).
Ring closure to the Amo ring was made possible by sacrific-
ing the OH group of the a-hydroxy-b2-amino acid isoSer.
Therefore, Amo represents a constrained b2-amino acid de-
prived of a side chain.[15] For this reason, we exploited the op-
portunity to utilize a-substituted-a-hydroxy-b2, 2-amino acids
for the preparation of Amo-derivatives carrying an explicit pro-
teinogenic side chain. The isoSer derivatives are interesting
members of the b2-amino acid family that are present in many
bioactive compounds, for example, Taxol, bestatin, protease in-
hibitors ; therefore, several synthetic protocols have been de-
veloped for their synthesis in optically active form, including
asymmetric catalysis, enzymatic resolution, and the use of
chiral auxiliaries and building blocks.[15, 29]
As a prototype for a side chain substituted amino acid surro-
gate, we prepared the model nonracemic (S)- or (R)-a-methyl-
isoSer from a keto ester and nitromethane, using an adapta-
tion of the catalytic enantioselective Henry reaction reported
by Jørgensen (Scheme 7).[30] Methyl pyruvate was reacted with
nitromethane in the presence of CuII, TEA, and (R)- or (S)-tBu-
bisoxazoline (Box), giving high yields of (S)- or (R)-configured
b-nitro-a-hydroxy ester 6 a or 6 b, respectively.[31] Reduction of
the nitro group gave the (S)- or (R)-b2, 2-amino ester 7 a[32] or
7 b, and coupling with the other residues under MW irradiation
and standard coupling agents gave the linear homochiral tetra-
Scheme 5. Reaction of sarcosine-containing 2 i to Oxd-peptide 4.
Scheme 6. Regio and stereoselective reduction of the Amo ring.
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peptide 9 a or heterochiral 9 b, respectively. Treatment with
DSC and base afforded the b2, 2-homo-Freidinger lactam ana-
logues 10 a and 10 b, respectively, bearing a substituent at
each a-position, Scheme 7.
Conformational analysis
For the novelty represented by the Amo scaffolds, which incor-
porate (S)- or (R)-b2- or a b2, 2-amino acid, we decided to investi-
gate the conformations of the Amo-containing tetrapeptides.
Indeed, it is well known that the introduction of a b2-residue in
a peptide sequence can lead to secondary structures that are
quite different from that of sequences composed of all a-resi-
dues.[15, 19, 33]
Hofmann et al. have investigated, by systematic theoretical
analyses, the intrinsic conformational preferences of Ac-b-
amino amide monomers carrying single or multiple substitu-
tions at the Ca and Cb backbone atoms. The most stable con-
formations were found to be different types of six- and eight-
membered ring hydrogen-bonded structures (C6, C8) corre-
sponding to gauche rotamers around the CaCb bond, which
is a feature that is expected to promote local folding when in-
corporated into peptides.[33d,i]
In a similar way, initially we performed theoretical studies to
analyze the conformational preferences of representative
models of unsubstituted and a-substituted Amo monomers
that we identified in the structures Ac-3-methylAmo (11 a) and
Ac-3,5-dimethylAmo (11 b). According to the convention of
Banerjee and Balaram,[33a] the soft torsional degrees of freedom
in a b-amino acid are defined as f (N-Cb), q (Cb-Ca), and y
(Ca-C=O), respectively (Figure 3). It is apparent that the central
torsion angle q represents the most relevant geometric varia-
ble of Amo monomers.
The relative energies of the minimum-energy conformations
of the + g, trans, and g rotamers around angle q of 11 a and
11 b have been estimated for the gas phase with the aid of
theoretical studies,[34] employing the density functional theory.
The calculated relative energies in increasing order were: for
11 a, + g < trans <g ; for 11 b, + g <g < trans (Figure 3).
For both structures, the global minimum was a + g conformer
of q, which is consistent with the calculated geometries previ-
ously reported for b2- and disubstituted b2, 2-amino acids, al-
though the rigid angle y prevents the formation of the com-
monly observed six-membered hydrogen-bonded pseudocy-
cles (C6).[33] For 11 a, the g conformer was by far the less
stable. In contrast, the presence of the methyl substituent at
the 5-position of the Amo ring in 11 b strongly reduced the DE
between the + g global minimum and the g rotamer, where-
as the DE of the trans geometry was slightly higher (Figure 3).
It is plausible that the geometric preferences of the Amo
monomers could impact the conformations of Amo-containing
oligopeptides. The computations indicated that the introduc-
tion of bulk at the a position of the scaffold should increase
the population of folded structures compared with unsubsti-
tuted Amo (Figure 3) because in the former the more extend-
ed trans rotamer was the least stable. It is likely that when a-
substituted Amo scaffold 11 b is inserted into a peptide, the
preponderance of + g and g rotamers should further stabi-
lize folded geometries by intramolecular hydrogen-bonding. In
oligomers, the occurrence of inter-residue hydrogen bonds or
other interactions between monomers may significantly influ-
ence the stability relationships between competing alterna-
tives, although they are not the main driving force for the for-
mation of the corresponding conformers themselves.[19, 33] Fur-
thermore, polar solvents are expected to have an influence on
the stability and conformation of molecules, and generally
tend to reduce the DE between conformers.[33]
Scheme 7. Synthesis of peptides 10 containing the (S)- or (R)-configured 5-
methylAmo scaffold.
Figure 3. Minimum-energy conformations and relative energies of the + g,
trans, and g rotamers around the central backbone dihedral angle q of
model compounds 11 a and 11 b. A systematic conformational analysis
around f and q was performed in the gas-phase employing DFT; DE are
given in kcal mol1; f, q, and y, are given in parentheses in degrees; Amo is
rendered in balls and cylinders, the rest in sticks.
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To experimentally determine the conformations of oligomers
containing the Amo scaffolds, we performed a conformational
analysis by NMR spectroscopy of the model tetrapeptides 3 d
and 3 e, which include the unsubstituted (S)- or (R)-configured
Amo scaffold, respectively, and 10 a and 10 b containing (S)- or
(R)-5-methylAmo. To gain more information, analyses were also
performed on other Amo-peptides. The 1H NMR of the model
compounds were recorded either in CDCl3 or in 8:2 mixtures
of [D6]dimethyl sulfoxide (DMSO) and H2O; such mixed solvent
systems have been recommended by several authors as excel-
lent representatives of biological fluids.[35] The spectra showed
a single set of resonances, suggestive of conformational homo-
geneity or a rapid equilibrium between conformers.
In 100 % CDCl3, amide protons that are hydrogen bonded
are found downfield with respect to nonbonded protons. For
all Amo-oligopeptides, the chemical shifts of the amide pro-
tons appeared in the order AmoNH> ValNH> AlaNH. In partic-
ular, the all-(S)-sequences 3 d and 10 a showed AmoNH reso-
nances above 7.0 ppm, suggesting that these amide proton
were bonded to a significant extent.
The occurrence of intramolecular hydrogen-bonding was de-
duced by analyzing the variations of the NH chemical shifts
upon addition of increasing percentages of [D6]DMSO to solu-
tions of the compounds in CDCl3 (Figure 4).
During the titration of 3 e and 10 b, AlaNH and AmoNH ex-
hibited a moderate downfield shift, whereas ValNH was much
more sensitive. For 3 d, AmoNH was significantly less sensitive
than AlaNH and ValNH. In contrast, for 10 a, the chemical shifts
of AlaNH and ValNH showed a marked variation, whereas that
of AmoNH remained practically constant and was therefore
less accessible. This suggested that AmoNH could be involved
in a H-bond in 10 a.[36]
To gain more information, tripeptides 3 a and 3 c were ana-
lyzed by titration experiments (see the Supporting Informa-
tion). They both behaved in similar ways to tetrapeptides 3 d
and 10 a, namely showing that AmoNH was possibly involved
in a hydrogen bond; this observation reasonably excludes
ValOMe as H-bond acceptor in the tetrapeptides. The reversal
of configuration of residue 3, from (S) in 3 a to (R) in 3 c, also
seemed to be well tolerated.
Variable-temperature (VT) NMR experiments were used to
detect if amide protons were involved in intramolecular hydro-
gen-bonding or are solvent exposed. The analyses were per-
formed in CDCl3 and 8:2 mixture of [D6]DMSO/H2O (Table 2). In
CDCl3, 3 e and 10 b showed comparatively low Dd/Dt values
for ValNH with respect to AlaNH and AmoNH (for 3 e, Dd/Dt =
0.5 ppb/K; for 10 b, Dd/Dt =1.0 ppb/K),[37] suggestive of
a preference for conformations having hydrogen bonded
ValNH (jDd/Dt j less than or close to 2.0 ppb/K). For 3 d and
10 a, the Dd/Dt parameters in CDCl3 did not allow clear deduc-
tions to be made. In [D6]DMSO/H2O, the Dd/Dt parameters of
3 d, 3 e, and 10 b did not reveal any H-bonded amide proton.
In contrast, the chemical shift of AmoNH for 10 a was signifi-
cantly less sensitive to increasing temperature (Dd/Dt in
[D6]DMSO/H2O =2.1 ppb/K), indicating a plausible conforma-
tion having this amide proton involved in a hydrogen bond.
The model compounds were analyzed by 2D-ROESY. In
CDCl3 the spectra displayed a modest number of inter-residue
cross-peaks (not shown), which was indicative of conforma-
tional freedom. In contrast, in the biomimetic [D6]DMSO/H2O
(8:2) mixed solvent the spectra were much clearer, and re-
vealed meaningful inter-residue cross-peaks. For the experi-
mental details and all results, see the following paragraphs.
Very often, changes in solvent composition cause meaning-
ful changes in the shape of the peptides. Generally, apolar sol-
vents such as chloroform are expected to increase hydrogen
bonding, due to the absence of competitive solvation of
donors and acceptors by individual solvent molecules.[19, 36–38]
Apparently, for the Amo-tetrapeptides, VT NMR and titration
experiments in chloroform differently supported the possible
existence or not of hydrogen bonds, accounting for a scarce
conformational definition. This behavior was investigated and
confirmed by means of FTIR spectroscopy and electronic circu-
lar dichroism (ECD) in a noncompetitive solvent (CH2Cl2).
FTIR spectroscopy in CH2Cl2 was utilized to analyze the
amide stretching regions. Normally, nonbonded amide protons
show a peak above 3400 cm1, whereas bonded amide NH ex-
Figure 4. Variation of NH proton chemical shift (ppm) of 2 mm 3 d, 3 e, 10 a,
and 10 b in CDCl3 as a function of increasing [D6]DMSO (% v/v).
Table 2. Dd/Dt values (p.p.b./K) for the amide protons of 3 d, 3 e, 10 a,
10 b, in CDCl3 or 8:2 [D6]DMSO/H2O.
Compd Solvent AlaNH AmoNH ValNH
3 d CDCl3 5.1 4.9 2.9
[D6]DMSO/H2O
[a] 7.0 6.3 4.5
3 e CDCl3 7.0 4.0 0.5
[D6]DMSO/H2O
[a] 7.0 6.6 5.0
10 a CDCl3 4.2 4.1 2.4
[D6]DMSO/H2O
[a] 6.8 2.1 4.7
10 b CDCl3 6.7 3.9 1.0
[D6]DMSO/H2O
[a] 7.1 5.8 4.5
[a] Ratio 8:2.
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hibit a peak below 3400 cm1.[39] The spectra of each tetrapep-
tide showed a peak above 3400 cm1 and one or more peaks
below 3400 cm1 (see the Supporting Information), indicative
of equilibria between nonbonded and multiply bonded struc-
tures.
ECD is a widely used technique for studying protein and
peptide conformations. This technique is intrinsically a low-res-
olution method; however, it can furnish qualitative information
on the presence of ordered secondary structures, although not
too many examples on short peptides are reported.[40] ECD
spectra of the model tetrapeptides in CH2Cl2 (see the Support-
ing Information) showed a smooth, negative band centered at
approximately 240 nm. This observation could be compatible
with the occurrence of nonclassical b-turns, because the n-p*
band of the latter generally appear near 225 nm.[40]
On the one hand, the results of the various experiments in
noncompetitive environments could reflect the existence of
equilibria between diverse hydrogen bonded and nonbonded
structures, as well as distorted or weak intra-residue hydrogen
bonds, which can be observed in peptides composed of a-
and b-residues.[19, 33, 41] On the other hand, in DMSO/water mix-
ture, the analyses suggested higher conformational homoge-
neity. It has been demonstrated that cryoprotective mixtures
of high viscosities, such as DMSO/water, showed a remarkable
ability to favor compact structures representative of the bioac-
tive conformers over disordered structures.[35, 42]
As anticipated, the 2D-ROESY of the model compounds in
[D6]DMSO/H2O (8:2) mixture gave analyzable cross-peaks. Com-
pared with tetrapeptides 3 e and 10 b (not shown), the homo-
chiral 3 d and 10 a showed a larger number of short-range
inter-residue proton–proton correlations (Figure 5). In particu-
lar, 10 a also displayed several short-range cross-peaks be-
tween remote residues (for the complete list of cross-peaks,
see the Supporting Information), which was suggestive of
a folded structure.
Cross-peak intensities were ranked to infer plausible inter-
proton distances as restraints (see the Supporting Information).
Structures (50) consistent with ROESY were obtained by simu-
lated annealing with restrained molecular dynamics (MD) in
a box of explicit TIP3P equilibrated water molecules. With the
exception of Amo-Phe, the w bonds were set at 1808 ; indeed,
it is well established that peptides comprising only secondary
amide bonds adopt all-trans conformations.[43] In any case, the
absence of Ha(i)Ha(i+1) cross-peaks reasonably excluded the
occurrence of cis peptide bonds.[44] The structures were mini-
mized with the AMBER force field[45] and clustered by the rmsd
analysis of backbone atoms. For each peptide, this procedure
essentially gave one major cluster comprising the large majori-
ty of the structures. The representative structures of 3 d, 3 e,
10 a, and 10 b, with the lowest energy, were selected and ana-
lyzed (Figure 6).
In the ROESY-derived structures of the homochiral tetrapep-
tides 3 d and 10 a, the Ts-Ala and Val-OMe moieties occupied
the same side underneath the heterocycle. The Amo residue of
3 d displayed a + g conformation about the central dihedral
angle (q= + 428), and a partially bent disposition of the back-
bone (Figure 6). In contrast, the central dihedral angle of Amo
in 10 a presented a g conformation (q=538), and the pep-
tide adopted a folded geometry compatible with an atypical
turn centered on the dipeptide mimetic Amo-Phe. This secon-
dary structure was stabilized by a clear 2 7!1 type H-bond be-
tween AmoNH and PheC=O, in agreement with the VT NMR
temperature coefficient (Table 2). The representative structure
of 10 a shown in Figure 6 is characterized by the following di-
hedral angles (in degrees): Amo (f, q, y): 106, 53, 119;
Phe (f, y): + 83, + 143 (see also Figure 7). The distance be-
tween the amide nitrogen of Amo and the carbonyl oxygen of
Phe is 3.0 , whereas that between AlaCa and PheCa is ap-
proximately 4.3 .
For tetrapeptides 3 e and 10 b, which include (R)-Amo scaf-
folds, the ROESY derived structures revealed more extended
backbone conformations, with Ts-Ala and Val-OMe positioned
on opposite sides of the Amo ring. For both compounds, the
central dihedral angle of Amo adopted a g conformation
(3 e : q=648 ; 10 b : q=558). The marked differences be-
tween homo- and heterochiral peptides are not unexpected
because it is well known that short sequences may experience
dramatic changes of backbone conformation by reversal of the
configuration of even a single residue.[2, 6, 11]
To analyze the dynamic behavior of the peptides, starting
from the structures of Figure 6, we performed unrestrained
Figure 5. Sketches of the structures of 3 d and 10 a, and short-range (distan-
ces 3 ) proton–proton ROESY correlations, indicated by arrows. Intraresi-
due and long-range (>3 ) correlations are not shown. Grey dashed arrows
connect protons belonging to consecutive residues (i,i + 1), whereas black
solid arrows connect protons of non-consecutive residues (i,i + 2 or i,i + 3).
Figure 6. Representative lowest energy structures 3 d, 3 e, 10 a, and 10 b, cal-
culated by restrained MD in a 30  30  30  box of standard TIP3P water
molecules. Backbones and Amo rings are rendered in balls and cylinders,
the rest in sticks.
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MD simulations for 10 ns at 300 K in a box of explicit TIP3P
water molecules. For all compounds, during the simulations
the complete rotation of the Phe-Val moiety around the Amo-
Phe bond was not observed; possibly, the two carbonyl
groups at the 2- and 4-positions of the Amo ring prevented
this movement. Analyses of the trajectories of 10 a showed
that the folded geometry of the backbone was maintained
during the simulation, although AmoNH and PheC=O were
prone to rotate about the dihedral angles Amof and Phey, re-
spectively, leading to occasional fluctuation of the distance
PheC=O-AmoN (see the Supporting Information). Analyses of
the trajectories of 3 d, 3 e, and 10 b, did not reveal the occur-
rence of clear secondary structures (not shown), and confirmed
the higher backbone mobility of heterochiral 3 e and 10 b.
The role exerted by the residue i + 3 on peptide conforma-
tion was not investigated. It can be expected that substitution
of Phe3 with other amino acids could modify the stability and
geometry of the folded conformation.[8a, 11c] It was shown that
peptides incorporating a central lactam-Gly pair can exhibit
high conformational heterogeneity around the lactamGly
bond, depending on the presence and relative disposition of
the substituents of the lactam scaffold.[8a, 11b]
On reviewing the evidence obtained from the experimental
results and theoretical computations, it can be perceived that
the conformational features of 3 d, 3 e, and 10 b, seem to be
governed mainly by the stereochemistry and geometric prefer-
ences of the Amo scaffold, which preferentially adopt a + g ori-
entation of the central torsion angle q (the g conformation
of (R)-Amo is equivalent to the + g of the (S)-enantiomer). For
10 a, a significant population of bent conformers was expected
on the basis of the higher stability of the g conformer
(Figure 3), which is correlated, in turn, to the presence of the
a-substituent on the Amo scaffold. This effect and the stabili-
zation exerted by the nine-membered hydrogen bond ring
appear to be the major contributors to the folding of peptide
10 a.
The conformation adopted by the model peptide 10 a in
a solvent mimetic of biological fluids can be regarded as
a pseudo b-turn, being characterized by a Ca(i) to Ca(i+3) dis-
tance of less than 7.0 .[47] This structure requires only the
mixed b/a-dipeptide to display the closed hydrogen-bonded
network (Figure 7 a). The dipeptide Amo-Phe contains a nine-
membered hydrogen-bonded ring between AmoNH and
PheC=O of type 2 7!1. This structure is in contrast to native b-
turns (Figure 7 b), which involve four residues to form the hy-
drogen-bonded structure in the opposite direction (residues
1 7!4). To our knowledge, 10 a represents a very rare example
of a short sequence showing this kind of pseudo b-turn,[48] al-
though it was observed in linear oligomers composed of repet-
itive a/b-units (e.g. , Figure 7 c, d).
The secondary structure formed by a given type of hybrid
a/b-oligomer depends on the number and type of substitution
of the a- or b-residues within the units, on their stereochemis-
try pattern, and on conformational restraints such as the incor-
poration of cyclic structures within the amino acid. A variety of
secondary structures have been reported, stabilized by 10- to
15-membered hydrogen-bonded rings in both orientations of
the backbone direction, whereas nine-membered hydrogen-
bonded rings of type 2 7!1 have been described less often.[19, 33]
Hofmann et al. carried out a detailed theoretical study of a/
b-peptides, demonstrating the stability of a mixed helix with
a nine-membered hydrogen-bond in the forward direction and
an 11-membered hydrogen-bond in the backward direction of
the peptide chain in apolar solvents.[33f] In contrast, the peptide
Boc-[(R)-Phe-(R)-b3-homo-Val]2-(R)-PheOMe (Figure 7 c),
[46] ‘heter-
ochiral’ because the b3-residues derived from l-a-residues, was
shown to adopt a mixed structure characterized by one classic
11-membered i7!i + 3 hydrogen bond, and a distinct nine-
membered 2 7!1 hydrogen-bond with opposite orientation.[49]
More recently, the 27!1 nine-membered hydrogen-bond
ring was described by Sanjayan and Rajamohanan[47] in oligo-
peptide foldamers consisting of the repeating building blocks
l-Pro and anthranilic acid, the latter as a rigid b-amino acid
(Figure 7 d). The structure was explained as the result of the
combined intrinsic conformational preferences of two local
constraints and the repetitive a/b-hybrid structure.[19] Replac-
ing Pro with other residues had an adverse effect on the stabi-
lization of this architecture. Later studies confirmed the stabili-
ty of the turn motifs featuring the nine-membered hydrogen-
bond ring also in tripeptides containing a distinct Ant-Pro scaf-
fold.[48]
Remarkably, the characteristic Freidinger-lactam-like struc-
ture of the mixed b2/a-dipeptide mimetic Amo-Phe induced
10 a to adopt, in a very competitive and biomimetic environ-
ment, a significant population of folded geometries, without
the concomitant assistance of further constraint-inducers, and
without the cooperative effect of repetitive units.
Conclusion
The cyclization of isoSer incorporated into short peptides with
DSC and DIPEA was performed either in solution or in the solid
phase with very good yields, and allowed the preparation, in
Figure 7. a) Sketch of the pseudo b-turn of 10 a stabilized by a nine-mem-
bered 27!1 H-bond induced by the (S)-Amo scaffold, and relevant dihedral
angles (deg). b) Ideal b-turn showing the ten-membered 1 7!4 H-bond;
c) The peptide in ref. [46]is characterized by nine-membered 2 7!1 H-bonds
(grey dashed arrows) as observed for 10 a, and distinct 11-membered i7!
i + 3 hydrogen bonds with opposite orientation; d) anthranilic acid-Pro[47]
scaffold showing the nine-membered 27!1 H-bond, and relevant dihedral
angles (deg).
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a single step, of peptidomimetics containing the unusual ami-
nomethyloxazolidin-2,4-dione (Amo) scaffold comprising isoSer
and the following residue. This unusual scaffold represents an
unprecedented b2-homo variant of the classic Freidinger
lactam. Furthermore, the availability of optically pure a-substi-
tuted a-hydroxy-b2, 2-amino acids allowed the preparation of
peptidomimetics carrying a single proteinogenic side chain at
each residue. Conformational analyses indicated that the con-
strained a-substituted Amo tends to favor in homochiral oligo-
mers a rare pseudo b-turn stabilized by a nine-membered hy-
drogen bond ring of type 2 7!1 in the opposite direction of the
sequence.
For the simple synthetic protocol and the atypical geometric
features, the Amo ring deserves to be exploited for the design
of new conformationally biased peptidomimetics or foldamers.
The scope of the Amo scaffold will be extended by introducing
substituents with defined stereochemistry in the b-position of
the Amo motif, thus providing constrained b2, 3-amino acid
building blocks. Further studies are in progress in our group
for the preparation and analysis of the conformational prefer-
ence of oligopeptides composed of repetitive Amo units,
either alone or in combination with other residues.
Experimental Section
General methods
Standard chemicals [including Boc- or Fmoc-protected a-amino
acids, (S)- and (R)-H-isoSerOH, Fmoc-rac-H-isoSerOH, (S)- and (R)-H-
PheNH2, H-ValOMe, H-SarNH2], were purchased from commercial
sources and used without further purification. Flash chromatogra-
phy was performed on silica gel (230–400 mesh), using mixtures of
distilled solvents. Compound purities were assessed by analytical
RP-HPLC and elemental analysis. Analytical RP-HPLC was performed
with an Agilent 1100 series apparatus, using a RP column [Phe-
nomenex mod. Gemini 3m C18 110A 100  3.0 mm (P/No 00D-4439-
Y0)] ; column description: stationary phase octadecyl carbon chain-
bonded silica (C18) with TMS endcapping, fully porous organo-
silica solid support, particle size 3 mm, pore size 110 , length
100 mm, internal diameter 3 mm; DAD 210 nm; mobile phase:
from H2O/CH3CN (9:1) to a H2O/CH3CN (2:8) in 20 min at a flow
rate of 1.0 mL min1, followed by 10 min at the same composition.
Semi-preparative RP-HPLC was performed with an Agilent 1100
series apparatus, using a RP column [ZORBAX mod. Eclipse XDB-
C18 PrepHT cartridge 21.2  150 mm 7m (P/No 977150–102)] ;
column description: stationary phase octadecyl carbon chain-
bonded silica (C18), double endcapped, particle size 7 mm, pore
size 80 , length 150 mm, internal diameter 21.2 mm; DAD
210 nm; mobile phase from H2O/CH3CN (8:2) to CH3CN (100 %) in
10 min at a flow rate of 12 mL min1. Chiral HPLC analysis was per-
formed with an Agilent 1200 series apparatus, using a CHIRALPAK
IC column (P/No 83325); column description: chiral stationary
phase cellulose tris(3,5-dichlorophenylcarbamate) immobilized on
silica, particle size 5 mm, length 250 mm, internal diameter 4.6 mm,
DAD 210/254 nm; mobile phase: n-hexane/2-propanol (3:1), at
0.8 mL min1. The RP-HPLC of compounds 3 h, H-Phe-ValOMe, 7,
and Ts-Ala-a-Me-isoSerOH, was performed as reported above, with
the addition of 0.1 % TFA in the mobile phase, and setting DAD at
254 nm. MS (ESI) analysis was performed using a MS single quadru-
pole HP 1100 MSD detector, with a drying gas flow of 12.5 L min1,
nebulizer pressure 30 psgi, drying gas temp. 350 8C, capillary volt-
age 4500 (+) and 4000 (), scan 50–2600 amu. Elemental analyses
were performed with a Thermo Flash 2000 CHNS/O analyzer. High
quality IR were obtained at 2 cm1 resolution with an FTIR spec-
trometer and 1 mm NaCl solution cell. ECD spectra were recorded
with a Jasco J-710 spectropolarimeter. The synthetic procedures by
MW irradiation were performed with a microwave oven (Micro-
SYNTH Microwave Labstation for Synthesis) equipped with a built-
in ATC-FO advanced fiber optic automatic temperature control.
1H NMR spectra were recorded with a Varian Gemini apparatus at
400 MHz in 5 mm tubes, using 0.01 m peptide at RT. Solvent sup-
pression was performed by the solvent presaturation procedure
implemented in Varian (PRESAT). 13C NMR spectra were recorded at
100 MHz. Chemical shifts are reported as d values relative to resid-
ual CHCl3 (dH = 7.26 ppm), DMSO (dH = 2.50 ppm), and CDCl3 (dC =
77.16 ppm) as internal standards. The unambiguous assignment of
1H NMR resonances was based on 2D gCOSY experiments. VT-
1H NMR experiments were performed over the range of 298–348 K;
temperature calibration was done with the ethylene glycol OH-
CHn chemical-shift separation method.
Boc-(S)-isoSer-(S)-PheNH2 (1 a): A stirred solution of Boc-isoSer-OH
(0.20 g, 1.0 mmol) in CH2Cl2/DMF (4:1, 5 mL) was treated with HOBt
(0.16 g, 1.2 mmol) and HBTU (0.46 g, 1.2 mmol), at r.t. , under a ni-
trogen atmosphere. After 5 min, H-PheNH2 (0.18 g, 1.1 mmol) and
DIPEA (0.42 mL, 2.4 mmol) were added, and the mixture was stirred
under a nitrogen atmosphere under MW irradiation. The micro-
wave-assisted reaction was performed with an initial irradiation
power of 150 W, and monitoring the internal reaction temperature
at 80 8C with a built-in ATC-FO advanced fiber optic automatic tem-
perature control. After 10 min, the mixture was concentrated at re-
duced pressure and the residue was diluted with EtOAc (25 mL).
The solution was washed with 0.1 m HCl (5 mL), and a saturated so-
lution of NaHCO3 (5 mL). The organic layer was dried over Na2SO4
and the solvent was evaporated at reduced pressure. Peptide 1 a
was isolated (0.29 g, 80 %, 91 % pure by analytical RP-HPLC, see
General Methods, Rt = 4.33 min) by flash chromatography over
silica gel (EtOAc/MeOH, 95:5). 1H NMR (CDCl3): d= 1.34 (s, 9 H; tBu),
3.00–3.17 (m, 2 H; PheHb), 3.20–3.36 (m, 2 H; isoSerHb), 4.10 (m,
1 H; isoSerHa), 4.59 (q, J = 6.8 Hz, 1 H; PheHa), 5.38 (br. t, 1 H; iso-
SerNH), 6.29 (s, 1 H; CONH2), 6.79 (s, 1 H; CONH2), 7.08–7.12 (m, 3 H;
PheArH), 7.12–7.20 (m, 2 H; PheArH), 7.61 ppm (br. d, 1 H; PheNH);
MS (ESI): m/z : 374.4 [M+Na]+ found: 374.4.
Boc-(S)-isoSer-(R)-PheNH2 (1 b) and Boc-(R)-isoSer-(S)-PheNH2
(1 c): The reaction of Boc-isoSerOH and (R)-H-PheNH2, or (R)-Boc-iso-
SerOH and H-PheNH2, using the same reagent quantities and
under same MW-assisted conditions described for the preparation
of 1 a, afforded dipeptides 1 b or 1 c, respectively. After the same
work up, crude 1 b,c were precipitated from MeOH/Et2O and col-
lected by filtration. The crude peptides were identified by MS (ESI),
and purity was assessed by analytical RP-HPLC (General Methods).
Compound 1 b : Yield: 86 % (76 % pure); Rt = 4.01 min; MS (ESI): m/
z calcd 352.4 [M+1]+ found: 352.2.
Compound 1 c : Yield: 85 % (78 % pure); Rt = 3.49 min; MS (ESI): m/z
calcd 352.4 [M+1]+ found: 352.3.
Boc-(S)-isoSer-(S)-Phe-ValOMe (1 d) and Boc-(R)-isoSer-(S)-Phe-
ValOMe (1 e): Boc-Phe-ValOMe[22] (1.13 g, 3.0 mmol) was N-depro-
tected according to the General Procedure for Boc Deprotection,
giving H-Phe-ValOMe-TFA salt in quantitative yield (90 % pure by
analytical RP-HPLC, see General methods, Rt = 1.82 min), identified
by MS (ESI) analysis (m/z calcd 279.2 [M+1]+ found: 279.2). The
crude dipeptide was coupled with Boc-isoSerOH or Boc-(R)-isoSer-
OH by using the same quantities and under same conditions de-
scribed for the preparation of 1 a, affording dipeptides 1 d or 1 e,
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respectively. After the same work up, crude 1 d,e were analyzed by
RP-HPLC ESI-MS (General Methods).
Compound 1 d : Yield: 82 % (75 % pure); Rt = 4.30 min; MS (ESI): m/
z calcd 466.2 [M+1]+ found: 466.1.
Compound 1 e : Yield: 80 % (73 % pure); Rt = 4.62 min; MS (ESI): m/z
calcd [M+1]+ 466.2 found: 466.2.
General procedure for Boc deprotection
The intermediate N-Boc peptides 1 (1.0 mmol) were deprotected
by treatment with 25 % TFA in CH2Cl2 (5 mL) while stirring at r.t.
After 15 min, the solution was evaporated under reduced pressure,
and the treatment was repeated. The residue was suspended in
ice-cold Et2O (20 mL). The intermediate peptide-TFA salts, which
precipitated in almost quantitative yields, were collected by centri-
fuge, and used for the next couplings without further purification
(80–85 % pure by analytical RP-HPLC, General Methods).
General procedure for the synthesis of peptides 2 e–f
The N-deprotected peptide-TFA salts prepared from peptides 1 as
described above were subjected to coupling with Tosyl (Ts)-AlaOH
or Boc-AlaOH in the same scale by using the same procedure uti-
lized for 1 a, giving the corresponding tri- or terapeptides 2 a–e or
2 f, respectively. After the usual workup, the peptides were isolated
(80–85 %) by flash chromatography over silica gel (EtOAc/MeOH,
95:5).
Ts-(S)-Ala-(S)-isoSer-(S)-PheNH2 (2 a): 90 % pure by RP-HPLC (Gen-
eral Methods); Rt = 4.86 min;
1H NMR (CDCl3): d= 1.00 (d, J = 6.8 Hz,
3 H; AlaMe), 2.37 (s, 3 H; TsMe), 2.71 (ddd, J = 5.0, 8.2, 13.8 Hz, 1 H;
isoSerHb), 2.88 (dd, J = 7.8, 13.8 Hz, 1 H; PheHb), 3.02 (dd, J = 5.0,
13.8 Hz, 1 H; PheHb), 3.20 (ddd, J = 4.4, 6.2, 13.8 Hz, 1 H; isoSerHb),
3.73 (dq, J = 5.2, 6.8 Hz, 1 H; AlaHa), 3.79 (dd, J = 4.4, 8.2 Hz, 1 H;
isoSerHa), 4.49 (ddd, J = 5.0, 5.6, 7.8, 1 H; PheHa), 5.86 (d, J =
5.2 Hz, 1 H; AlaNH), 7.16–7.27 (m, 5 H; PheArH), 7.35 (m, 2 H;
TsArH3,5), 7.51 (s, 1 H; CONH2), 7.63–7.69 (m, 3 H; TsArH2,6 and
PheNH), 7.77 (dd, J = 5.0, 6.2 Hz, 1 H; isoSerNH), 7.86 ppm (s, 1 H;
CONH2) ; MS (ESI): m/z calcd 477.2 [M+H]
+ found: 477.4.
Ts-(S)-Ala-(R)-isoSer-(S)-PheNH2 (2 b): 88 % pure by RP-HPLC (Gen-
eral Methods); Rt = 4.16 min;
1H NMR (CDCl3): d= 0.99 (d, J = 6.8 Hz,
3 H; AlaMe), 2.36 (s, 3 H; TsMe), 2.86–2.98 (m, 2 H; isoSerHb and
PheHb), 3.01 (dd, J = 4.8, 13.9 Hz, 1 H; PheHb), 3.22 (ddd, J = 4.6,
6.2, 13.8 Hz, 1 H; isoSerHb), 3.74 (dq, J = 5.0, 6.8 Hz, 1 H; AlaHa),
3.78 (dd, J = 4.6, 8.0 Hz, 1 H; isoSerHa), 4.46 (ddd, J = 4.8, 5.7,
7.6 Hz, 1 H; PheHa), 5.79 (d, J = 5.0 Hz, 1 H; AlaNH), 7.16–7.27 (m,
5 H; PheArH), 7.35 (m, 2 H; TsArH3,5), 7.51 (s, 1 H; CONH2), 7.64–7.67
(m, 3 H; TsArH2,6 and PheNH), 7.75 (dd, J = 4.8, 6.2 Hz, 1 H; iso-
SerNH), 7.85 ppm (s,1 H; CONH2) ; MS (ESI): m/z calcd 477.2 [M+H]
+
found: 477.4.
Ts-(S)-Ala-(S)-isoSer-(R)-PheNH2 (2 c): 91 % pure by RP-HPLC (Gen-
eral Methods); Rt = 4.45 min;
1H NMR (CDCl3): d= 1.18 (d, J = 7.0 Hz,
3 H; AlaMe), 2.42 (s, 3 H; TsMe), 3.04 (dd, J = 8.2, 14.0 Hz, 1 H;
PheHb), 3.23 (dd, J = 6.0, 14.0 Hz, 1 H; PheHb), 3.63 (ddd, J = 4.8,
8.2, 13.8 Hz, 1 H; isoSerHb), 3.68–3.78 (m, 2 H; AlaHa and isoSerHb),
4.16 (m, 1 H; isoSerHa), 4.49 (dd, J = 6.0, 6.4, 8.2 Hz, 1 H; PheHa),
5.32 (d, J = 2.4 Hz, 1 H; isoSerOH), 5.93 (d, J = 7.6 Hz, 1 H; AlaNH),
6.34 (s, 1 H; CONH2), 6.79 (s, 1 H; CONH2), 7.18–7.31 (m, 7 H; TsArH3,5
and PheArH), 7.61 (d, J = 6.4 Hz, 1 H; PheNH), 7.68 (dd, J = 4.8,
6.0 Hz, 1 H; isoSerNH), 7.75 ppm (m, 2 H; TsArH2,6) ; MS (ESI): m/z
477.4.
Ts-(S)-Ala-(S)-isoSer-(S)-Phe-(S)-ValOMe (2 d): 89 % pure by RP-
HPLC (General Methods); Rt = 4.90 min;
1H NMR (CDCl3): d= 0.84 (d,
J = 6.6 Hz, 3 H; ValMe), 0.87 (d, J = 6.8 Hz, 3 H; ValMe), 1.17 (d, J =
6.8 Hz, 3 H; AlaMe), 2.10 (m, 1 H; ValHb), 2.41 (s, 3 H; TsMe), 3.13 (d,
J = 7.6 Hz, 2 H; PheHb), 3.41 (ddd, J = 5.6, 6.4, 14.0 Hz, 1 H; iso-
SerHb), 3.49 (ddd, J = 6.0, 8.0, 14.0 Hz, 1 H; isoSerHb), 3.69 (s, 3 H;
OMe), 3.79 (dq, J = 6.8, 7.6 Hz, 1 H; AlaHa), 4.13 (ddd, J = 4.6, 6.0,
6.4 Hz, 1 H; isoSerHa), 4.44 (dd, J = 5.2, 8.4 Hz, 1 H; ValHa), 4.70 (dt,
J = 7.6, 8.0 Hz, 1 H; PheHa), 5.04 (d, J = 4.6 Hz, 1 H; isoSerOH), 6.14
(d, J = 7.6 Hz, 1 H; AlaNH), 6.92 (d, J = 8.4 Hz, 1 H; ValNH), 7.18–7.30
(m, 7 H; PheArH and TsArH3,5), 7.51 (dd, J = 5.6, 8.0 Hz, 1 H; iso-
SerNH), 7.52 (d, J = 8.0 Hz, 1 H; PheNH), 7.73 ppm (m, 2 H; TsArH2,6) ;
MS (ESI): m/z calcd 591.4 [M+H]+ found: 591.3.
Ts-(S)-Ala-(R)-isoSer-(S)-Phe-(S)-ValOMe (2 e): 92 % pure by RP-
HPLC (General Methods); Rt = 4.78 min;
1H NMR (CDCl3): d= 0.93 (d,
J = 6.8 Hz, 3 H; ValMe), 0.95 (d, J = 7.2 Hz, 3 H; ValMe), 1.15 (d, J =
7.2 Hz, 3 H; AlaMe), 2.15 (m, 1 H; ValHb), 2.45 (s, 3 H; TsMe), 3.00
(dd, J = 7.4, 13.9 Hz, 1 H; PheHb), 3.08 (dd, J = 6.9, 13.9 Hz, 1 H;
PheHb), 3.43 (ddd, J = 3.0, 5.2, 14.2 Hz, 1 H; isoSerHb), 3.74 (s, 3 H;
OMe), 3.87–3.95 (m, 2 H; AlaHa and isoSerHb), 4.20 (dd, J = 3.0,
6.2 Hz, 1 H; isoSerHa), 4.51 (dd, J = 5.8, 8.1 Hz, 1 H; ValHa), 4.55
(ddd, J = 6.9, 7.4, 8.0 Hz, 1 H; PheHa), 6.39 (d, J = 8.1 Hz, 1 H;
ValNH), 7.19–7.34 (m, 10 H; PheArH + TsArH3,5 + AlaNH + PheNH +
isoSerNH), 7.77 ppm (m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd 591.4
[M+H]+ found: 590.3.
Boc-(S)-Ala-(S)-isoSer-(S)-Phe-(S)-ValOMe (2 f): 87 % pure by RP-
HPLC (General Methods); Rt = 4.86 min;
1H NMR (CDCl3): d (two
conformers in 6:4 ratio) = 0.80 (d, J = 7.2 Hz, 3 H; ValMe), 0.83 (d,
J = 6.8 Hz, 3 H; ValMe), 1.21* and 1.26 (d, J = 6.8 Hz, 3 H; AlaMe),
1.37 (s, 9 H; tBu), 2.05 (m, 1 H; ValHb), 3.01–3.11 (m, 2 H; PheHb),
3.35 (m, 1 H; isoSerHb), 3.48 (m, 1 H; isoSerHb), 3.65 (s, 3 H; OMe),
4.03–4.08 (m, 2 H; AlaHa and isoSerHa), 4.38 (m, 1 H; ValHa), 4.63
(br. q, 1 H; PheHa), 5.05 and 5.31* (br. d, 1 H; AlaNH), 6.84 (br. d,
1 H; ValNH), 7.19–7.23 (m, 6 H; PhArH and isoSerNH), 7.55 ppm
(br. d, J = 8.4 Hz, 1 H; PheNH) (* major conformation); MS (ESI): m/z
calcd 536.7 [M+H]+ found: 536.6.
Solid-phase synthesis of Ac-(S)-Ala-(S/R)-Amo-(S)-Phe-Wang
(2 h)
Wang resin preloaded with Fmoc-PheOH (0.5 g, 0.4–0.8 mmol g1,
resin particle size: 100–200 mesh) was introduced into a reactor for
SPPS. Fmoc was removed with DMF/piperidine (4:1, 5 mL) under
MW irradiation for 1 min under mechanical shaking (40 W, monitor-
ing the internal temperature at 45 8C with a built-in ATC-FO ad-
vanced fiber optic automatic temperature control). The suspension
was filtered, the resin was washed with CH2Cl2 (5 mL) and treated
with a second portion of DMF/piperidine as described above. The
suspension was then filtered, and the resin was washed three
times in sequence with CH2Cl2 (5 mL) and MeOH (5 mL).
All coupling steps were performed according to the following Gen-
eral Procedure. The resin was swollen in CH2Cl2 (5 mL), and a solu-
tion of the Fmoc-N-protected amino acid (0.6 mmol) and HOBt
(0.6 mmol) in DMF (4 mL) was added at r.t. and under a nitrogen
atmosphere, followed by HBTU (0.6 mmol) and DIPEA (1.2 mmol).
The mixture was mechanically shaken under MW irradiation as de-
scribed above and, after 10 min, the resin was filtered and washed
three times with the sequence CH2Cl2 (5 mL) and MeOH (5 mL).
Coupling efficacy was determined by means of the Kaiser test. All
subsequent deprotection steps were performed as reported above.
Ts-Ala-isoSer-SarNH2 (2 i): Boc-isoSerOH and H-SarNH2 were cou-
pled in the same quantities and by the same procedure utilized for
the preparation of 1 a (MW-assisted peptide synthesis). The crude
Boc-isoSer-SarNH2 was recovered as described for 1 b,c (85 %, 78 %
pure by analytical RP-HPLC, General methods, Rt = 3.17 min). The
dipeptide was N-deprotected according to the General Procedure
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for Boc Deprotection, and the corresponding peptide-TFA salt was
coupled with Ts-AlaOH under the conditions described above.
Compound 2 i was isolated (70 %, 92 % pure by analytical RP-HPLC,
see General Methods, Rt = 3.54 min) by flash chromatography over
silica gel (EtOAc/MeOH, 95:5). 1H NMR (CDCl3): d (major confor-
mer) = 1.11 (d, J = 7.2 Hz, 3 H; AlaMe), 2.37 (s, 3 H; TsMe), 3.45 (s,
3 H; SarMe), 3.64–3.76 (m, 2 H; isoSerHb and AlaHa), 3.82 (J = 4.4,
6.2, 13.8 Hz, 1 H; isoSerHb), 4.14 (d, J = 18.2 Hz, 1 H; SarHa), 4.20 (d,
J = 18.2 Hz, 1 H; SarHa), 4.90 (br. t, 1 H; isoSerHa), 6.31 (d, J =
6.8 Hz, 1 H; AlaNH), 6.90 (s, 1 H; CONH2), 7.20 (s, 1 H; CONH2), 7.35
(m, 2 H; TsArH3,5), 7.53 (dd, J = 5.0, 6.2 Hz, 1 H; isoSerNH), 7.66 ppm
(m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd 401.1 [M+H]
+ found: 401.2.
Solution-phase synthesis of Amo-peptides 3 a–g, 10 a, and
10 b
DSC (0.36 mmol) was added to a stirred solution of 1 (0.33 mmol)
in CH2Cl2/DMF (3:1, 4 mL) followed by DIPEA (0.07 mmol) at r.t. and
under a nitrogen atmosphere. After 1 h, the solvent was removed
under reduced pressure, the residue was diluted with 0.1 m HCl
(5 mL), and the mixture was extracted with CH2Cl2 (3  5 mL). The
combined organic layers were dried over Na2SO4, the solvent was
evaporated under reduced pressure, and the residue was purified
by semipreparative RP-HPLC (General Methods).
Ts-(S)-Ala-(S)-Amo-(S)-PheNH2 (3 a): 95 % pure by RP-HPLC (Gener-
al Methods); Rt = 6.41 min;
1H NMR (CDCl3): d= 1.17 (d, J = 6.8 Hz,
3 H; AlaMe), 2.42 (s, 3 H; TsMe), 3.48–3.58 (m, 3 H; PheHb and
AmoHb), 3.69 (ddd, J = 4.0, 6.4, 13.8 Hz, 1 H; AmoHb), 3.78 (dq, J =
6.4, 6.8 Hz, 1 H; AlaHa), 4.73 (dd, J = 4.0, 7.6 Hz, 1 H; AmoHa), 4.93
(t, J = 8.4 Hz, 1 H; PheHa), 6.10 (br. d, J = 6.4 Hz, 1 H; AlaNH), 6.24 (s,
1 H; CONH2), 6.52 (s, 1 H; CONH2), 7.09 (br. t, 1 H; AmoNH), 7.19 (m,
2 H; TsArH3,5), 7.20–7.34 (m, 5 H; PhArH), 7.72 ppm (m, 2 H; TsArH2,6) ;
13C NMR (CDCl3): d= 18.4, 21.5, 33.8, 38.9, 52.7, 56.8, 76.7, 127.2,
127.5, 128.9, 129.5, 129.9, 135.8, 136.3, 144.0, 154.7, 170.1, 171.6,
172.9 ppm; MS (ESI): m/z calcd 503.2 [M+H]+ found: 503.3; ele-
mental analysis calcd (%) for C23H26N4O7S: C 54.97, H 5.21, N 11.15,
S 6.38; found: C 54.14, H 5.28, N 11.28, S 6.51.
Ts-(S)-Ala-(R)-Amo-(S)-PheNH2 (3 b): 96 % pure by RP-HPLC (Gener-
al Methods); Rt = 6.32 min;
1H NMR (CDCl3): d= 1.15 (d, J = 7.1 Hz,
3 H; AlaMe), 2.43 (s, 3 H; TsMe), 3.37 (ddd, J = 4.4, 4.8, 14.6 Hz, 1 H;
AmoHb), 3.52 (d, J = 8.7 Hz, 2 H; PheHb), 3.80 (dq, J = 7.1, 8.2 Hz,
1 H; AlaHa), 4.12 (ddd, J = 4.2, 7.6, 14.6 Hz, 1 H; AmoHb), 4.70 (dd,
J = 4.2, 4.4 Hz, 1 H; AmoHa), 4.97 (t, J = 8.7 Hz, 1 H; PheHa), 6.28
(m, 2 H; CONH2 and AlaNH), 6.41 (s, 1 H; CONH2), 6.99 (dd, J = 4.8,
7.6 Hz, 1 H; AmoNH), 7.23–7.31 (m, 5 H; PheArH), 7.33 (m, 2 H;
TsArH3,5), 7.73 ppm (m, 2 H; TsArH2,6) ;
13C NMR (CDCl3): d= 18.7,
21.3, 33.2, 38.5, 52.5, 55.8, 76.7, 126.8, 127.0, 128.5, 128.6, 129.5,
136.1, 137.0, 143.3, 153.9, 169.3, 170.8, 172.6 ppm; MS (ESI): m/z
calcd 503.2 [M+H]+ found: 503.3; elemental analysis calcd (%) for
C23H26N4O7S: C 54.97, H 5.21, N 11.15, S 6.38; found: C 56.07, H
5.11, N 10.93, S 6.27.
Ts-(S)-Ala-(S)-Amo-(R)-PheNH2 (3 c): 95 % pure by RP-HPLC (Gener-
al Methods); Rt = 6.88 min;
1H NMR (CDCl3): d= 1.11 (d, J = 7.2 Hz,
3 H; AlaMe), 2.42 (s, 3 H; TsMe), 3.45–3.52 (m, 3 H; AmoHb and
PheHb), 3.75–3.84 (m, 2 H; AlaHa and AmoHb), 4.69 (dd, J = 4.0,
4.4 Hz, 1 H; AmoHa), 4.91 (dd, J = 6.4, 9.9 Hz, 1 H; PheHa), 6.25 (d,
J = 7.2 Hz, 1 H; AlaNH), 6.47 (s, 1 H; CONH2), 6.79 (s, 1 H; CONH2),
7.18–7.31 (m, 8 H; TsArH3,5 and PheArH and AmoNH), 7.73 ppm (m,
2 H; TsArH2,6) ;
13C NMR (CDCl3): d= 18.3, 21.0, 33.0, 38.5, 52.2, 55.6,
76.6, 126.6, 126.7, 128.3, 128.4, 129.3, 136.0, 136.8, 143.0, 153.8,
169.1, 170.3, 172.4 ppm; MS (ESI) m/z calcd 503.2 [M+H]+ found:
503.3; elemental analysis calcd (%) for C23H26N4O7S: C 54.97, H 5.21,
N 11.15, S 6.38; found: C 55.62, H 5.16, N 11.24, S 6.20.
Ts-(S)-Ala-(S)-Amo-(S)-Phe-(S)-ValOMe (3 d): 96 % pure by RP-HPLC
(General Methods); Rt = 6.55 min;
1H NMR (CDCl3): d= 0.81 (d, J =
6.4 Hz, 3 H; ValMe), 0.88 (d, J = 6.8 Hz, 3 H; ValMe), 1.13 (d, J =
7.2 Hz, 3 H; AlaMe), 2.14 (m, 1 H; ValHb), 2.39 (s, 3 H; TsMe), 3.44
(ddd, J = 3.5, 5.2, 14.4 Hz, 1 H; AmoHb), 3.53 (d, J = 8.6 Hz, 2 H;
PheHb), 3.63 (ddd, J = 4.0, 6.0, 14.4 Hz, 1 H; AmoHb), 3.73 (s, 3 H;
OMe), 3.82 (dq, J = 7.2, 8.6 Hz, 1 H; AlaHa), 4.51 (dd, J = 4.8, 8.6 Hz,
1 H; ValHa), 4.67 (dd, J = 3.5, 4.0 Hz, 1 H; AmoHa), 4.95 (t, J = 8.6 Hz,
1 H; PheHa), 5.79 (d, J = 8.6 Hz, 1 H; AlaNH), 6.81 (d, J = 8.6 Hz, 1 H;
ValNH), 7.00 (dd, J = 5.2, 6.0 Hz, 1 H; AmoNH), 7.23–7.33 (m, 7 H;
PheArH2 and TsArH3,5), 7.68 ppm (m, 2 H; TsArH2,6) ;
13C NMR (CDCl3):
d= 17.8, 18.8, 18.9, 21.4, 30.9, 34.1, 38.9, 52.3, 52.4, 57.4, 57.9, 77.3,
127.0, 127.4, 128.8, 128.9, 129.6, 135.7, 136.9, 143.5, 154.4, 167.5,
171.1, 172.2, 172.5 ppm; MS (ESI): m/z calcd 617.2 [M+H]+ found:
617.5; elemental analysis calcd (%) for C29H36N4O9S: C 56.48, H 5.88,
N 9.09, S 5.20; found: C 55.35, H 5.76, N 9.27, S 5.32.
Ts-(S)-Ala-(R)-Amo-(S)-Phe-(S)-ValOMe (3 e): 94 % pure by RP-HPLC
(General Methods); Rt = 6.98 min;
1H NMR (CDCl3): d= 0.81 (d, J =
6.8 Hz, 3 H; ValMe), 0.89 (d, J = 6.4 Hz, 3 H; ValMe), 1.14 (d, J =
7.0 Hz, 3 H; AlaMe), 2.14 (m, 1 H; ValHb), 2.44 (s, 3 H; TsMe), 3.28
(ddd, J = 3.0 3.4, 14.4 Hz, 1 H; AmoHb), 3.54 (dd, J = 8.0, 14.6 Hz,
1 H; PheHb), 3.58 (dd, J = 8.4, 14.6 Hz, 1 H; PheHb), 3.77 (s, 3 H;
OMe), 3.87 (dq, J = 7.0, 8.8 Hz, 1 H; AlaHa), 4.28 (ddd, J = 4.1, 9.0,
14.4 Hz, 1 H; AmoHb), 4.49 (dd, J = 5.0, 8.2 Hz, 1 H; ValHa), 4.76 (dd,
J = 3.0, 4.1 Hz, 1 H; AmoHa), 5.03 (dd, J = 8.0, 8.4 Hz, 1 H; PheHa),
6.21 (d, J = 8.8 Hz, 1 H; AlaNH), 6.41 (d, J = 8.2 Hz, 1 H; ValNH), 6.78
(dd, J = 3.4, 9.0 Hz, 1 H; AmoNH), 7.30–7.34 (m, 5 H; PheArH), 7.38
(m, 2 H, TsArH3,5), 7.72 ppm (m, 2 H; TsArH2,6) ;
13C NMR (CDCl3): d=
17.8, 18.7, 18.9, 21.5, 30.9, 34.0, 38.3, 52.4, 52.9, 55.5, 58.3, 77.8,
127.0, 127.1, 127.9, 128.8, 128.9, 129.2, 129.4, 129.8, 129.9, 135.3,
137.1, 143.7, 153.9, 167.4, 171.2, 171.5, 172.5 ppm; MS (ESI): m/z
calcd 617.2 [M+H]+ found: 617.5; elemental analysis calcd (%) for
C29H36N4O9S: C 56.48, H 5.88, N 9.09, S 5.20; found: C 55.57, H 5.97,
N 8.90, S 5.04.
Boc-(S)-Ala-(S)-Amo-(S)-Phe-(S)-ValOMe (3 f): 95 % pure by RP-
HPLC (General Methods); Rt = 7.02 min;
1H NMR (CDCl3): d= 0.84 (d,
J = 6.4 Hz, 3 H; ValMe), 0.92 (d, J = 6.8 Hz, 3 H; ValMe), 1.25 (d, J =
6.0 Hz, 3 H; AlaMe), 1.42 (s, 9 H; tBu), 2.18 (m, 1 H; ValHb), 3.42
(ddd, J = 4.4, 5.6, 14.4 Hz, 1 H; AmoHb), 3.53 (d, J = 8.5 Hz, 2 H;
PheHb), 3.76 (s, 3 H; OMe), 3.84 (ddd, J = 4.8, 7.2, 14.4 Hz, 1 H;
AmoHb), 4.16 (m, 1 H; AlaHa), 4.56 (dd, J = 4.8, 8.2 Hz, 1 H; ValHa),
4.74 (dd, J = 4.4, 4.8 Hz, 1 H; AmoHa), 4.95 (t, J = 8.5 Hz, 1 H;
PheHa), 5.30 (br. d, 1 H; AlaNH), 6.81 (d, J = 8.2 Hz, 1 H; ValNH), 6.87
(dd, J = 5.6, 7.2 Hz, 1.H; AmoNH), 7.23–7.34 ppm (m, 5 H; PheArH);
13C NMR (CDCl3): d= 17.6, 18.5, 18.9, 25.4, 25.5, 28.2, 30.9, 34.2,
38.8, 50.0, 52.4, 57.3, 57.7, 76.6, 127.5, 128.6, 128.8, 129.0, 135.5,
152.1, 154.4, 168.7, 171.4, 172.3, 173.9 ppm; MS (ESI): m/z calcd
585.3 [M+Na]+ found: 585.3; elemental analysis calcd (%) for
C27H38N4O9 : C 57.64, H 6.81, N 9.96; found: C 56.66, H 6.95, N 10.11.
Boc-(S)-Amo-(S)-PheNH2 (3 g): 96 % pure by RP-HPLC (General
Methods); Rt = 6.88 min;
1H NMR (CDCl3): d= 1.42 (s, 9 H; tBu), 3.23
(ddd J = 4.4, 5.4, 14.6 Hz, 1 H; AmoHb), 3.43 (ddd, J = 4.0, 7.8,
14.6 Hz, 1 H; AmoHb), 3.46–3.53 (m, 2 H; PheHb), 4.70 (dd, J = 4.0,
4.8 Hz, 1 H; AmoHa), 4.85–4.94 (m, 2 H; AmoNH and PheHa), 5.84
(br. s, 1 H; CONH2), 6.43 (br. s, 1 H; CONH2), 7.20 (d, J = 6.8 Hz, 2 H;
PheArH), 7.26–7.35 ppm (m, 3 H; PheArH); 13C NMR (CDCl3): d=
28.2, 33.5, 38.5, 56.0, 79.8, 80.9, 127.1, 128.7, 128.4, 136.5, 154.3,
155.7, 169.4, 171.1 ppm; MS (ESI): m/z calcd 400.2 [M+Na]+ found:
400.4; elemental analysis calcd (%) for C18H23N3O6 : C 57.29, H 6.14,
N 11.13; found: C 58.43, H 6.26, N 10.91.
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Solid-phase synthesis of Ac-(S)-Ala-(S/R)-Amo-(S)-PheOH (3 h)
The resin-bound peptide 2 h was suspended in CH2Cl2/DMF (3:1,
4 mL), and DSC (0.9 mmol) and DIPEA (0.3 mmol) were added at r.t.
and under a nitrogen atmosphere. The reaction was conducted
under mechanical shaking for 2 h, then the suspension was filtered
and the resin was washed three times in sequence with CH2Cl2
(5 mL) and MeOH (5 mL).
The resin-bound peptide was suspended in a solution of TFA
(4.8 mL), H2O (0.20 mL), and phenol (0.050 g), in CH2Cl2 (5 mL), and
mechanically shaken at r.t. After 2 h, the mixture was filtered, the
resin was washed with 10 % TFA in Et2O (2  5 mL) and Et2O (2 
5 mL). The filtrate and washes were collected and solvent and vola-
tiles were removed at r.t. under N2 flow. The resulting residue was
suspended in ice-cold Et2O, and the crude solid that precipitated
was triturated and collected by centrifuge. Amo-peptide acid 3 h
was isolated as a 1:1 mixture of diastereoisomers by semiprepara-
tive RP-HPLC (see General Methods) (80 % based on the average
resin loading of 0.6 mmol g1; >95 % pure by analytical RP-HPLC).
1H NMR ([D6]DMSO): d= 1.14 and 1.16 (d, J = 8.0 Hz, 6 H; AlaMe),
1.81 (s, 6 H; Ac), 2.83 (ddd, J = 3.2, 4.0, 14.2 Hz, 1 H; AmoHb), 3.17–
3.29 (m, 3 H; AmoHb and PheHb), 3.38–3.48 (m, 3 H; AmoHb and
PheHb), 3.49 (ddd, J = 3.6, 8.6, 14.4 Hz, 1 H; AmoHb), 4.17–4.26 (m,
2 H; AlaHa), 4.82–4.94 (m, 2 H; PheHa), 4.97 (dd, J = 3.6, 7.2 Hz, 1 H;
AmoHa), 5.10 (dd, 3.2, 7.6 Hz, 1 H; AmoHa), 7.18–7.30 (m, 10 H;
PhArH), 7.90 (br. d, 1 H; AlaNH), 7.92–8.04 (m, 2 H; AlaNH and
AmoNH), 8.19 ppm (br. t, 1 H; AmoNH); 13C NMR ([D6]DMSO): d=
18.1, 18.2, 33.0, 33.1, 48.0, 48.1, 54.2, 54.5, 77.8, 78.1, 126.9, 128.1,
128.5, 128.8, 128.9, 129.1, 136.6, 136.7, 154.0, 168.9, 169.0, 170.3,
170.4, 172.1, 172.7. 173.0, 173.1 ppm; MS (ESI): m/z calcd [M+H]+
392.2; found: 392.2; elemental analysis calcd (%) for C18H21N3O7: C
55.24, H 5.41, N 10.74; found: C 54.14, H 5.52, N 10.55.
Ts-Ala-Oxd-SarNH2 (4): A solution of peptide 2 i (0.1 g, 0.25 mmol)
in CH2Cl2/DMF (3:1, 4 mL) was treated with DSC (0.20 g,
0.75 mmol) and DBU (38 mL, 0.25 mmol) at 40 8C and under a nitro-
gen atmosphere. After 6 h, the reaction was stopped and workup
was performed as described for the synthesis of 3 a–g. The Oxd-
peptide 4 was isolated by semipreparative RP-HPLC (58 mg, 55 %,
94 % pure by RP-HPLC; General Methods; Rf = 4.60 min).
1H NMR
(CDCl3): d (major conformer) = 1.32 (d, J = 7.3 Hz, 3 H; AlaMe), 2.40
(s, 3 H; TsMe), 3.47 (s, 3 H; SarMe), 3.90 (dd, J = 4.2, 8.6 Hz, 1 H;
OxdH4), 4.09 (d, J = 18.0 Hz, 1 H; SarHa), 4.12 (dd, J = 8.6, 9.3 Hz,
1 H; OxdH4), 4.24 (d, J = 18.0 Hz, 1 H; SarHa), 5.11 (dq, J = 7.3,
8.8 Hz, 1 H; AlaHa), 5.45 (dd, J = 4.2, 9.3 Hz, 1 H; OxdH5), 6.07 (br. s,
1 H; CONH2), 6.38 (br. s, 1 H; CONH2), 6.44 (m, 2 H; CONH2 and
AlaNH), 7.18 (m, 2 H; TsArH3,5), 7.75 ppm (m, 2 H; TsArH2,6) ;
13C NMR
([D6]DMSO): d= 18.5, 20.8, 39.1, 38.6, 50.7, 60.5, 85.4, 128.3, 129.3,
137.6, 141.5, 153.1, 168.4, 169.1, 175.0 ppm; MS (ESI): m/z calcd
[M+H]+ 427.1; found: 427.1; elemental analysis calcd (%) for
C17H22N4O7S: C 47.88, H 5.20, N 13.14; found: C 47.11, H 5.12, N
13.29.
Ts-(S)-Ala-(4R,5R)-4-hydroxy-5-aminomethylOxd-(S)-PheNH2 (5):
NaBH4 (4 mmol) was added to a solution of 3 b (0.4 mmol) in
MeOH (4 mL) at 0 8C under a nitrogen atmosphere. The mixture
was stirred for 7 h, then the reaction was stopped with acetone
(4 mL). The reaction mixture was concentrated under reduced pres-
sure and the residue was diluted with water (5 mL), and extracted
with CH2Cl2 (3  5 mL). The collected organic layers were dried with
Na2SO4, filtered, and concentrated under reduced pressure. The
residue was purified by semipreparative RP-HPLC (see General
Methods) to give 5 (85 %, 95 % pure by RP-HPLC, general Methods,
Rf = 5.12 min).
1H NMR (CDCl3): d= 1.17 (d, J = 6.8 Hz, 3 H; AlaMe),
2.44 (s, 3 H; TsMe), 3.04 (ddd, J = 3.4, 5.0, 14.6 Hz; CH2N), 3.14–3.25
(m, 2 H; CH2N and PheHb) 3.34 (dd, J = 7.6, 14.0 Hz, 1 H; PheHb),
3.73 (dq, J = 6.8, 7.2 Hz, 1 H; AlaHa), 4.35 (br. t, 1 H; OxdH5), 4.84
(dd, J = 7.6, 8.6 Hz, 1 H; PheHa), 5.21 (br. s, 1 H; OxdH4), 5.95 (br. s,
1 H; CONH2), 6.03 (d, J = 7.2 Hz, 1 H; AlaNH), 6.63 (br. s, 1 H;;
CONH2), 7.08 (dd, J = 5.0, 6.8 Hz, 1 H; CH2NH), 7.27–7.35 (m, 7 H;
PhArH and TsArH3,5), 7.73 ppm (m, 2 H; TsArH2,6) ;
13C NMR (CDCl3):
d= 19.2, 20.8, 34.8, 40.1, 52.7, 60.2, 79.7, 81.6, 125.7, 127.0, 127.6,
128.8, 129.0, 129.3, 130.1, 135.5, 138.1, 144.2, 157.3, 171.2,
172.9 ppm elemental analysis calcd (%) for C23H28N4O7S: C 54.75, H
5.59, N 11.10, S 6.36; found: C 53.98, H 5.64, N 11.32, S 6.55; MS
(ESI): m/z calcd [M+Na]+ 527.2; found: 527.0.
Ts-(S)-Ala-(S)-a-Me-isoSerOMe (8 a): Nitromethane (1.5 mL), methyl
pyruvate (50 mL, 0.5 mmol), and TEA (14 mL, 0.1 mmol) were mixed
in the presence of Cu(OTf)2 (36 mg, 0.10 mmol) and 2,2’-isopropyli-
denebis[(4R)-4-tert-butyl-2-oxazoline] (31 mg, 0.10 mmol), as de-
scribed previously (Ref.[30] main text). The reaction mixture was fil-
tered through a plug of silica, and solvent was removed under re-
duced pressure. The resulting crude a-nitro-(S)-hydroxy ester 6 a,
which was obtained in quantitative yield, was identified by RP-
HPLC-ESI analysis, and utilized without further purification (81 mg,
99 %, 85 % pure by RP-HPLC analysis; Rt = 2.04 min; 87 % ee as de-
termined by chiral HPLC analysis of the crude mixture, see General
Methods). MS (ESI): m/z calcd [M+Na]+ 186.1; found: 186.2. Com-
pound 6 a was dissolved in EtOH (6 mL) and treated with 10 % Pd/
C (100 mg) and H2 at atmospheric pressure for 6 h at r.t. to give,
after filtration over Celite and evaporation of solvent under re-
duced pressure, 3-amino-2-hydroxy-2-methyl-propionic ester 7 a
(67 mg, 99 %, 82 % pure by RP-HPLC analysis, see General Methods;
Rt = 1.67 min), which was utilized for the next step without purifica-
tion. MS (ESI): m/z calcd [M+H]+ 134.1; found: 134.1. Crude 7 a
was coupled with Ts-AlaOH (120 mg, 0.5 mmol) by using the same
procedure described for the synthesis of 1 a. After the usual
workup, dipeptide 8 a (140 mg, 80 %, 88 % pure by RP-HPLC analy-
sis, see General Methods; Rt = 3.85 min) was isolated by flash chro-
matography over silica gel (EtOAc/cyclohexane, 2:8). 1H NMR
(CDCl3): d= 1.25 (d, J = 6.7 Hz, 3 H; AlaMe), 1.40 (s, 3 H; Me-isoSer),
2.44 (s, 3 H; TsMe), 3.32 (dd, J = 6.0, 14.0 Hz; isoSerHb), 3.66–3.83
(m, 5 H; AlaHa and Me-isoSerHb and COOMe), 4.95 (br. d, J =
8.4 Hz, 1 H; AlaNH), 6.47 (dd, J = 5.0, 6.0 Hz, 1 H; isoSerNH),7.33 (m,
2 H; TsArH3,5), 7.75 ppm (m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd
[M+H]+ 359.1; found: 359.3.
Ts-(S)-Ala-(R)-a-Me-isoSerOMe (8 b): The reaction of nitromethane
and methyl pyruvate in the same quantities as described for the
preparation of 6 a in the presence of 2,2’-isopropylidenebis[(4S)-4-
tert-butyl-2-oxazoline], gave 6 b in quantitative yield (87 % pure by
RP-HPLC analysis; Rt = 2.04 min; 89 % ee as determined by chiral
HPLC analysis of the crude mixture, see General Methods). MS
(ESI): m/z calcd [M+Na]+ 186.1; found: 186.1. The reduction to b-
amino ester 7 b and coupling with Ts-AlaOH gave 8 b, after purifica-
tion by flash chromatography (150 mg, 84 %; 93 % pure by RP-
HPLC analysis, see General Methods; Rt = 3.85 min) was done as de-
scribed for 8 a. 1H NMR (CDCl3): d= 1.23 (d, J = 6.7 Hz, 3 H; AlaMe),
1.37 (s, 3 H; Me-isoSer), 2.44 (s, 3 H; TsMe), 3.20 (dd, J = 4.8, 13.6 Hz,
1H; isoSerHb), 3.66–3.83 (m, 5 H; AlaHa and isoSerHb and COOMe),
5.06 (br. d, J = 8.0 Hz, 1 H; AlaNH), 6.65 (br. t, 1 H; isoSerNH), 7.33
(m, 2 H; TsArH3,5), 7.75 (m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd [M+H]
+
359.1; found: 359.3.
Ts-(S)-Ala-(S)-a-Me-isoSer-(S)-Phe-(S)-ValOMe (9 a): Dipeptide ester
8 a (140 mg, 0.39 mmol) was dissolved in MeOH (2 mL) and treated
with 1 m LiOH (1 mL) while stirring. After 6 h, the pH was adjusted
to 7 with 0.1 m HCl and the solvent was removed under reduced
pressure to give Ts-Ala-a-Me-isoSerOH (128 mg, 95 %, 90 % pure by
RP-HPLC analysis, see General Methods; Rt = 2.35 min). MS (ESI): m/
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z calcd [M+H]+ 345.1; found: 345.2. The residue was suspended in
CH2Cl2/DMF (4:1, 5 mL) and treated with HOBt, HBTU, DIPEA, and
H-Phe-ValOMe under MW irradiation as described for the prepara-
tion of 1 a. After the usual workup, tetrapeptide 9 a (0.20 g, 85 %,
90 % pure by analytical RP-HPLC, see General Methods; Rf =
4.99 min) was isolated by flash chromatography over silica gel
(EtOAc). 1H NMR (CDCl3): d= 0.79 (d, J = 5.8 Hz, 3 H; ValMe), 0.82 (d,
J = 6.8 Hz, 3 H; ValMe), 1.09 (d, J = 6.8 Hz, 3 H; AlaMe), 1.22 (s, 3 H;
a-Me-isoSer), 2.07 (m, 1 H; ValHb), 2.36 (s, 3 H; TsMe), 3.05 (dd, J =
8.0, 14.8 Hz, 1 H; PheHb), 3.10 (dd, J = 6.8, 14.8 Hz, 1 H; PheHb),
3.29 (d, J = 5.8 Hz, 2 H; isoSerHb), 3.63 (s, 3 H; OMe), 3.67 (dq, J =
6.8, 7.6 Hz, 1 H; AlaHa), 4.38 (dd, J = 4.8, 8.0 Hz, 1 H; ValHa), 4.48
(ddd, J = 6.8, 7.6, 8.0 Hz, 1 H; PheHa), 6.69 (d, J = 7.6 Hz, 1 H;
AlaNH), 6.96 (d, J = 8.0 Hz, 1 H; ValNH), 7.17–7.27 (m, 7 H; PheArH
and TsArH3,5), 7.38 (t, J = 5.8 Hz, 1 H; isoSerNH), 7.50 (d, J = 7.6 Hz,
1 H; PheNH), 7.66 ppm (m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd
[M+H]+ 605.3; found: 605.5.
Ts-(S)-Ala-(R)-a-Me-isoSer-(S)-Phe-(S)-ValOMe (9 b): Dipeptide
ester 8 b (150 mg, 0.42 mmol) was treated with 1 m LiOH in MeOH
as described for 7 a, affording the dipeptide acid (134 mg, 95 %,
85 % pure by RP-HPLC analysis, see General Methods; Rt =
2.38 min) after the same reaction workup. MS (ESI): m/z calcd
[M+H]+ 345.1; found: 345.3. Ts-Ala-(R)-a-Me-isoSerOH was coupled
with H-Phe-ValOMe, as described for the preparation of 9 a. Tetra-
peptide 9 b (0.21 g, 83 %, 91 % pure by analytical RP-HPLC, see
General Methods; Rf = 5.11 min) was isolated after the same work
up described for 9 a. 1H NMR (CDCl3): d= 0.87 (d, J = 5.6 Hz, 3 H;
ValMe), 0.86 (d, J = 6.8 Hz, 3 H; ValMe), 1.03 (d, J = 7.2 Hz, 3 H;
AlaMe), 1.15 (s, 3 H; a-Me-isoSer), 2.06 (m, 1 H; ValHb), 2.35 (s, 3 H;
TsMe), 2.89 (dd, J = 8.0, 14.2 Hz, 1 H; PheHb), 3.05 (dd, J = 6.4,
14.2 Hz, 1 H; PheHb), 3.17 (dd, J = 5.6, 13.6 Hz, 1 H; isoSerHb), 3.51
(dd, J = 6.8, 13.6 Hz, 1 H; isoSerHb), 3.65 (s, 3 H; OMe), 3.76 (dq, J =
7.2, 7.8 Hz, 1 H; AlaHa), 4.40 (dd, J = 5.8, 8.2 Hz, 1 H; ValHa), 4.53
(ddd, J = 6.4, 7.6, 8.0 Hz, 1 H; PheHa), 6.80 (d, J = 7.8 Hz, 1 H;
AlaNH), 7.09–7.15 (m, 3 H; ValNH and PheArH3,5), 7.18–7.26 (m, 6 H;
PheArH2,4,6 and TsArH3,5 and isoSerNH), 7.35 (d, J = 7.6 Hz, 1 H;
PheNH), 7.66 (m, 2 H; TsArH2,6) ; MS (ESI): m/z calcd [M+H]
+ 605.3;
found: 605.5.
Ts-(S)-Ala-(S)-5-Me-Amo-(S)-Phe-(S)-ValOMe (10 a): The cyclization
of 9 a in solution as reported for 3 a–g followed by the same
workup of the reaction and isolation by semipreparative RP-HPLC,
afforded 10 a (95 %, 96 % pure by analytical RP-HPLC, see General
methods; Rt = 7.23 min).
1H NMR (CDCl3): d= 0.87 (d, J = 7.2 Hz, 3 H;
ValMe), 0.94 (d, J = 7.2 Hz, 3 H; ValMe), 1.14 (d, J = 6.8 Hz, 3 H;
AlaMe), 1.31 (s, 3 H; AmoMe), 2.22 (m, 1 H; ValHb), 2.42 (s, 3 H;
TsMe), 3.33 (dd, J = 4.8, 14.4 Hz, 1 H; AmoHb), 3.49 (dd, J = 7.4,
14.0 Hz, 1 H; PheHb), 3.55 (dd, J = 10.4, 14.0 Hz, 1 H; PheHb), 3.67
(dd, J = 7.6, 14.4 Hz, 1 H; AmoHb), 3.80 (s, 3 H; OMe), 3.88 (dq, J =
6.8, 8.8 Hz, 1 H; AlaHa), 4.57 (dd, J = 4.6, 8.2 Hz, 1 H; ValHa), 4.95
(dd, J = 7.4, 10.4 Hz, 1 H; PheHa), 5.64 (d, J = 8.8 Hz, 1 H; AlaNH),
6.76 (d, J = 8.2 Hz, 1 H; ValNH), 6.97 (dd, J = 4.8, 7.6 Hz, 1 H;
AmoNH), 7.24–7.36 (m, 7 H; PheArH and TsArH3,5), 7.70 ppm (m,
2 H; TsArH2,6) ;
13C NMR (CDCl3): d= 17.5, 19.0, 19.3, 19.7, 21.5, 31.0,
34.4, 43.5, 52.2, 52.7, 57.8, 58.1, 84.3, 127.0, 127.1, 127.9, 128.8,
128.8, 128.9, 129.1, 129.3, 129.7, 129.9, 135.0, 137.2, 143.5, 153.6,
167.7, 172.2, 172.5, 174.6 ppm; MS (ESI): m/z calcd [M+H]+ 631.2;
found: 631.1; elemental analysis calcd (%) for C30H38N4O9S: C 57.13,
H 6.07, N 8.88, S 5.08; found: C 58.27, H 6.18, N 8.81, S 4.97.
Ts-(S)-Ala-(R)-5-Me-Amo-(S)-Phe-(S)-ValOMe (10 b). The cyclization
of 9 b in solution as reported for 3 a–g and 9 a followed by the
same workup of the reaction and isolation by semipreparative RP-
HPLC afforded 10 b (92 % 97 % pure by analytical RP-HPLC, see
General Methods; Rt = 7.45 min).
1H NMR (CDCl3): d= 0.87 (d, J =
7.2 Hz, 3 H; ValMe), 0.94 (d, J = 7.2 Hz, 3 H; ValMe), 1.13 (d, J =
7.2 Hz, 3 H; AlaMe), 1.23 (s, 3 H; AmoMe), 2.19 (m, 1 H; ValHb), 2.44
(s, 3 H; TsMe), 3.12 (dd, J = 3.6, 14.4 Hz, 1 H; AmoHb), 3.48 (dd, J =
9.6, 14.0 Hz, 1 H; PheHb), 3.54 (dd, J = 7.8, 14.0 Hz, 1 H; PheHb),
3.79 (s, 3 H; OMe), 3.86 (dq, J = 7.2. 8.8 Hz, 1 H; AlaHa), 4.09 (dd, J =
9.2, 14.4 Hz, 1 H; AmoHb), 4.51 (dd, J = 4.8, 8.2 Hz, 1 H; ValHa), 4.99
(dd, J = 7.8, 9.6 Hz, 1 H; PheHa), 6.34 (d, J = 8.8 Hz, 1 H; AlaNH), 6.52
(d, J = 8.2 Hz, 1 H; ValNH), 6.76 (dd, J = 3.6, 9.2 Hz, 1 H; AmoNH),
7.19–7.32 (m, 5 H; PheArH), 7.38 (m, 2 H; TsArH3,5), 7.72 ppm (m,
2 H; TsArH2,6) ;
13C NMR (CDCl3): d= 18.0, 18.4, 18.6, 21.1, 22.1, 31.4,
33.2, 43.0, 51.8, 52.3, 55.4, 58.0, 84.2, 126.4, 126.7, 128.3, 128.6,
129.4, 136.0, 137.0, 142.9, 156.1, 167.6, 171.8, 172.1, 173.5. MS (MS):
m/z calcd [M+H]+ 631.2; found: 631.1; elemental analysis calcd (%)
for C30H38N4O9S: C 57.13, H 6.07, N 8.88, S 5.08; found: C 56.00, H
5.99, N 8.91, S 5.13.
ROESY and molecular dynamics
2D ROESY experiments in [D6]DMSO/H2O (8:2) were performed in
the phase-sensitive mode at r.t. , spin-locking field (gb2) was
2000 Hz, and mixing time was set to 250 ms; spectra were pro-
cessed in the hypercomplex approach; peaks were calibrated on
DMSO. Only ROESY-derived constraints were included in the re-
strained molecular dynamics.[50] Cross-peak intensities were classi-
fied as very strong, strong, medium, and weak, and were associat-
ed with distances of 2.3, 2.7, 3.3, and 5.0 , respectively.[51] The in-
tensities of the cross peaks arising from protons separated by
known distances (e.g. , geminal) were found to match with these
associations. Geminal and other clear correlations were discarded
as constraints. For the absence of Ha(i, i+1) ROESY cross peaks, all
of the w bonds were set at 1808 (force constant: 16 kcal mol1 2).
MD simulations
The restrained MD simulations were conducted at 300 K and 1 atm
by using the AMBER force field in a 30  30  30  box of standard
TIP3P models of equilibrated water.[52] Periodic boundary condi-
tions were applied, a dielectric constant of 1 was used, and the
cutoff distance for the nonbonded interactions was 12 . All water
molecules with atoms that come closer than 2.3  to a solute
atom were eliminated. A 100 ps simulation at 1200 K was used for
generating 50 random structures that were subsequently subjected
to a 50 ps restrained MD with a 50 % scaled force field at the same
temperature, followed by 50 ps with full restraints (distance force
constant of 7 kcal mol1 2), after which the system was cooled in
20 ps to 50 K. H-bond interactions were not included, nor were tor-
sion angle restraints. The resulting structures were minimized with
3000 cycles of steepest descent and 3000 cycles of conjugated gra-
dient (convergence of 0.01 kcal 1 mol1). The backbones of the
structures were clustered by the rmsd analysis.[50]
Unrestrained MD simulations[50] were performed starting with the
conformation derived from ROESY in a 30  30  30  box of stan-
dard TIP3P water for 10 ns at 298 K using periodic boundary condi-
tions, at constant temperature and pressure (Berendsen scheme,[53]
bath relaxation constant of 0.2). For 1–4 scale factors, van der
Waals and electrostatic interactions are scaled in AMBER to half
their nominal value. The integration time step was set to 0.1 fs.
The system coordinates were collected every picosecond.
Computational methods
Theoretical calculations and full molecular geometry optimizations
in the ground state have been performed in vacuo by using the
density functional theory (DFT)[54] methods implemented the Gaus-
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sian 09 package of programs.[34] In particular, calculations were car-
ried out by combining the three-parameter hybrid functional (B3)
for the exchange part[55] and the Lee–Yang–Parr (LYP)[56] to the 6–
311 + + G(d,p) basis set.
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